Literature DB >> 2126475

Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial.

T R Tubman1, H L Halliday, C Normand.   

Abstract

OBJECTIVE: To estimate the cost of treating babies with severe respiratory distress syndrome with natural porcine surfactant.
DESIGN: Retrospective controlled survey.
SETTING: Regional neonatal intensive care unit, Belfast. PATIENTS: 33 Preterm babies with severe respiratory distress syndrome who were enrolled in a European multicentre trial during 1985-7. 19 Babies were treated with surfactant and 14 served as controls.
INTERVENTIONS: Treatment with natural porcine surfactant. MAIN OUTCOME MEASURE: Cost associated with surfactant replacement treatment per extra survivor in the treatment group and cost per quality adjusted life year for each extra survivor.
RESULTS: Fifteen (79%) of the 19 treated babies and five (36%) of the 14 control babies survived. On average, the control babies required 20 days in hospital compared with 61 days for the treated babies (or 95 [corrected] days per extra survivor in the treatment group). The cost per extra survivor in the treatment group was pounds 13,720, with the cost per quality adjusted life year estimated at pounds 710.
CONCLUSION: These costs compare favourably with those of established forms of treatment in adults. Thus surfactant replacement treatment for severe respiratory distress syndrome is fairly inexpensive and cost effective.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126475      PMCID: PMC1663955          DOI: 10.1136/bmj.301.6756.842

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome.

Authors:  W M Maniscalco; J W Kendig; D L Shapiro
Journal:  Pediatrics       Date:  1989-01       Impact factor: 7.124

2.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

Review 3.  A review of the economics of care for sick newborn infants.

Authors:  M Mugford
Journal:  Community Med       Date:  1988-05

4.  Economic evaluation of neonatal intensive care of very-low-birth-weight infants.

Authors:  M H Boyle; G W Torrance; J C Sinclair; S P Horwood
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

5.  Costs and outcomes in a regional neonatal intensive care unit.

Authors:  B Newns; M F Drummond; G M Durbin; P Culley
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

6.  Cost of neonatal care.

Authors:  S Ryan; A Sics; P Congdon
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

7.  Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial.

Authors:  G Enhorning; A Shennan; F Possmayer; M Dunn; C P Chen; J Milligan
Journal:  Pediatrics       Date:  1985-08       Impact factor: 7.124

8.  Cost of neonatal intensive care for very-low-birthweight infants.

Authors:  B Sandhu; R C Stevenson; R W Cooke; P O Pharoah
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

  8 in total
  22 in total

1.  Development of audit measures and guidelines for good practice in the management of neonatal respiratory distress syndrome. Report of a Joint Working Group of the British Association of Perinatal Medicine and the Research Unit of the Royal College of Physicians.

Authors: 
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

Review 2.  Cost effectiveness of surfactant replacement in preterm babies.

Authors:  M Mugford; S Howard
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

3.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 4.  Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.

Authors:  D Coyle
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 5.  Introducing new cost effective treatments into the NHS. Surfactant treatment for premature babies: who cares enough to pay?

Authors:  H L Halliday
Journal:  Qual Health Care       Date:  1993-09

6.  Cost implications of different approaches to the prevention of respiratory distress syndrome.

Authors:  M Mugford; J Piercy; I Chalmers
Journal:  Arch Dis Child       Date:  1991-07       Impact factor: 3.791

7.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 8.  Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

Authors:  L R Wiseman; H M Bryson
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

9.  Limited comparability of classifications of levels of neonatal care in UK units. The ECSURF (Economic Evaluation of Surfactant) Collaborative Study Group.

Authors: 
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

10.  A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Authors:  Carlos G Guardia; Fernando R Moya; Sunil Sinha; Phillip D Simmons; Robert Segal; Jay S Greenspan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.